Vikram Purohit
Stock Analyst at Morgan Stanley
(0.91)
# 3,885
Out of 5,008 analysts
157
Total ratings
32.79%
Success rate
-11.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.74 | +57.49% | 3 | Aug 18, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $75 → $80 | $66.02 | +21.18% | 10 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.23 | -4.40% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $209.84 | +19.14% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $87.20 | -25.46% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $118.64 | +60.15% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $20.68 | +69.25% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.42 | +103.62% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $32.64 | -5.02% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $87.01 | -81.61% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.24 | +380.77% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $20.57 | -51.39% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $3.99 | +50.56% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $10.51 | +299.62% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $56.92 | -27.97% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $18.49 | +116.33% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.96 | +339.19% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $20.15 | +88.59% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $12.93 | +54.68% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.34 | -30.24% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.97 | +1,016.75% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $14.24 | +40.45% | 2 | Aug 5, 2020 |
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.74
Upside: +57.49%
Halozyme Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $75 → $80
Current: $66.02
Upside: +21.18%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.23
Upside: -4.40%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $209.84
Upside: +19.14%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $87.20
Upside: -25.46%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $118.64
Upside: +60.15%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $20.68
Upside: +69.25%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.42
Upside: +103.62%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $32.64
Upside: -5.02%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $87.01
Upside: -81.61%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $6.24
Upside: +380.77%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $20.57
Upside: -51.39%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $3.99
Upside: +50.56%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $10.51
Upside: +299.62%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $56.92
Upside: -27.97%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $18.49
Upside: +116.33%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.96
Upside: +339.19%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $20.15
Upside: +88.59%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $12.93
Upside: +54.68%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.34
Upside: -30.24%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.97
Upside: +1,016.75%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $14.24
Upside: +40.45%